Apligraf is a bioengineered skin product composed of neonatal fibroblasts and keratinocytes. The FDA has approved Apligraf for the treatment of chronic venous ulcers and diabetic ulcers.
Objective:
We review the development of bioengineered skin, examine the cellular activities of various growth factors that may facilitate wound healing, and discuss the results of clinical trials with a particular construct, Apligraf, as proof of principle.
Conclusion:
Bioengineered skin acts as a “smart” delivery system for growth factors and other stimulatory substances. Not only does it present a novel treatment for chronic and diabetic ulcers, but it could also be considered for application to other types of acute wounds.
Get full access to this article
View all access options for this article.
References
1.
EaglsteinWHFalangaV. Tissue engineering and the development of Graftskin, a human skin equivalent. Clin Ther1997; 19(5):895–905.
2.
O'ConnorNEMullikenJBBanks-Schege. Grafting of burns with cultured epithelium prepared from autologous epidermal cells. Lancet1981; 8211:75–78.
HasanAMurataHFalabellaA. Dermal fibroblasts from venous ulcers are unresponsive to the action of the transforming growth factor-β1. J Dermatol Sci1997; 16:59–66.
5.
CownAJHatzirodosNHoldingCA. Effect of healing on the expression of transforming growth factor beta(s) and their receptors in chronic venous leg ulcers. J Invest Dermatol2001; 117(5):1282–1289.
6.
CooperDMYuEZHennesseyP. Determination of endogenous cytokines in chronic wounds. Ann Surg1994; 219:688–692.
7.
FalangaVEaglsteinWH. The trap hypodiesis of venous ulceration. Lancet1993; 341:1006–1008.
8.
FalangaV. Graftskin treatment of venous ulcers and other chronic wounds. J Dermatol1998; 25:812–817.
9.
RivardAFabreJ-ESilverM. Age-dependent impairment of angiogenesis. Circulation1999; 99:111–120.
10.
GalzieZKinsellaARSmithJA. Fibroblast growth factor and their receptors. Biochem Cell Biol1997; 75:669–685.
11.
McKeehanWLWangFKanM. The heparan sulfate-fibroblast growth factor family: Diversity of structure and function. Prog Nucleic Acid Res Mol Biol1998; 59:135–176.
12.
ShimoTNakanishiTKimuraY. Inhibition of endogenous expression of connective tissue growth factor by its antisense oligonucleotide and antisense RNA suppresses proliferation and migration of vascular endothelial cells. J Biochem (Tokyo)1998; 124:130–140.
13.
DammeierJBrauchleMFalkW. Connective tissue growth factor: A novel regulator of mucosal repair and fibrosis in inflammatory bowel disease?Int J Biochem Cell Biol1998; 30:909–922.
14.
DammeierJBeerHDBrauchleM. Dexamethasone is a novel potent inducer of connective tissue growth factor expression. J Biol Chem1998; 273(29):18185–18190.
15.
AntonyakMAMoscatelloDKWongAJ. Constitutive activation of c-Jun N-terminal kinase by a mutant epidermal growth factor receptor. J Biol Chem1998; 273(5):2817–2822.
16.
ChaillerPMenardD. Ontogeny of EGF receptors in the human gut. Front Biosci1999; 4:D87–101.
GalzieZKinsellaARSmithJA. Fibroblast growth factor and their receptors. Biochem Cell Biol1997; 75:669–685.
19.
OrtegaSIttmannMTsangSH. Neuronal defects and delayed wound healing in mice lacking fibroblast growth factor 2. Proc Natl Acad Sci USA1998; 95:5672–5677.
20.
KlintPClaesson-WelshL. Signal transduction by fibroblast growth factor receptors. Front Biosci1999; 4:D165–177.
21.
TodoTKondoTNakamuraS. Neuronal localization of fibroblast growth factor-9 immunoreactivity in human and rat brain. Brain Res1998; 783:179–187.
22.
SolerPMWrightTESmithPD. In vivo characterization of keratinocyte growth factor-2 as a potential wound healing agent. Wound Repair Regen1999; 7(3): 172–178.
23.
RobsonMCPhillipsTJFalangaV. Randomized trial of topically applied repifermin (recombinant human keratinocyte growth factor-2) to accelerate wound healing in venous ulcers. Wound Repair Regen2001; 9(5):347–352.
24.
MatsuguchiTLillyMBKraftAS. Cytoplasmic domains of the human granulocyte–macrophage colony-stimulating factor (GM-CSF) receptor β chain (hβc) responsible for human GM–CSF-in-duced myeloid cell differentiation. J Biol Chem1998; 273(31):19411–19418.
25.
TorenANaglerA. The implications of granulocyte–monocyte colony-stimulating factor (GM–CSF) in cytotoxicity of bone marrow transplant. Cytokines Cell Mol Ther1998; 4(3):199–206.
26.
JaschkeEZaberniggAGattringerC. Recombinant human granulocyte–macrophage colony-stimulating factor applied locally in low doses enhances healing and prevents recurrence of chronic venous ulcers. Int J Dermatol1999; 38:380–386.
27.
Da CostaRMJesusFM RibeiroAnicetoC. Randomized, double-blind, placebo-controlled, dose-ranging study of granulocyte–macrophage colony stimulating factors in patients with chronic venous leg ulcers. Wound Repair Regen1999; 7:17–25.
JeschkeMCBarrowREHawkinsHK. Effect of multiple gene transfers on insulinlike growth factor I complementary DNA gene construct in rats after thermal injury. Arch Surg1999; 134:1137–1141.
32.
StylianouESaklatvalaJ. Interleukin-1. Int J Biochem Cell Biol1998; 30:1075–1079.
33.
MantovaniAMuzioMGhezziP. Regulation of inhibitory pathway of the interleukin-1 system. Ann NY Acad Sci1998; 840:338–351.
34.
SasakiKHattoriTFujisawaT. Nitric oxide mediates interleukin-1-induced gene expression of matrix metalloproteinases and basic fibroblast growth factor in cultured rabbit articular chondrocytes. J Biochem (Tokyo)1998; 123:431–439.
35.
SticeLLVaziriCFallerDV. Regulation of platelet-derived growth factor signaling by activated p21Ras. Front Biosci1999; 4:D72–86.
36.
WinklesJA. Serum and polypeptide growth factor-inducible gene expression in mouse fibroblast. Prog Nucleic Acid Res Mol Biol1998; 58:41–78.
37.
NicosiaRFVillaschiS. Autoregulation of angiogenesis by cells of the vessel wall. Int Rev Cytol1999; 185:1–43.
AgrenMSSteenfosHHDabelsteenS. Proliferation and mitogenic response to PDGF-BB of fibroblasts isolated from chronic venous leg ulcers is ulcer-age dependent. J Invest Dermatol1999; 112:463–469.
40.
NicosiaRFVillaschiS. Autoregulation of angiogenesis by cells of the vessel wall. Int Rev Cytol1999; 185:1–43.
41.
ZaherHFernandez-SalgueroPMLetterioJ. The involvement of aryl hydrocarbon receptor in the activation of transforming growth factor-β and apoptosis. Mol Pharmacol1998; 54(2):313–321.
PoltorakZCohenTSivanR. VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. J Biol Chem1997; 272(11):7151–7158.
44.
CarmelietPCollenD. Role of vascular endothelial growth factor and vascular endothelial growth factor receptors in vascular development. Curr Top Microbiol Immunol1999; 237:133–158.
45.
FerraraN. Vascular endothelial growth factor: Molecular and biological aspects. Curr Top Microbiol Immunol1999; 237:1–30.
46.
NeufeldGCohenTGengrinovitchS. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J1999'; 13:9–22.
47.
OrtegaNHutchingsHPlouetJ. Signal relays in the VEGF system. Front Biosci1999; 4:D141–152.
48.
LosordoDWValePRSymesJF. Gene therapy for myocardial angiogenesis: Initial clinical results with direct myocardial injection of ph VEGF165 as sole therapy for myocardial ischemia. Circulation1998; 98:2800–2804.
49.
HarperJKlagsbrunM. Cartilage to bone—Angiogenesis leads the way. Nat Md1999; 5:617–618.
50.
FalangaVMargolisDAlvarezO. Rapid healing of venous ulcers and lack of clinical rejection with an allogeneic cultured human skin equivalent. Arch Dermatol1998; 134(3):293–300.
51.
FalangaVSabolinskiM. A bilayered living construct (Graftskin) accelerates complete closure of hard-to-heal venous ulcers. J Invest Dermatol1999; 112(4):565.
52.
SibbaldRGWilliamsonDOrstedHL. Preparing the wound bed—debridement, bacterial balance, and moisture balance. Ostomy Wound Manage2000; 46(11):14–35.
53.
BrowneACVearncombeMSibbaldRG. High bacterial load in asymptomatic diabetic patients with neurotrophic ulcer retards wound healing after application of Dermagraft. Ostomy Wound Manage2001; 47(10):44–49.
54.
FalangaV. Venous ulceration. In: KrasnerDKaneD, eds. Chronic wound care: A clinical source book for health care professionalsCity: Health Management Publications, Inc., 1997, pp 165–171.
55.
SteedDLDonohoeDWebsterMW. Effect of extensive debridement and treatment on the healing of diabetic foot ulcers. J Am Coll Surg1996; 183(1):61–64.
56.
EaglsteinWHAlvarezOMAulettaM. Acute excisional wounds treated with a tissue-engineered skin (Graftskin)Dermatol Surg1999; 25(3):195–201.
57.
BadiavasEMehtaPPFalangaV. Retrovirally-mediated gene transfer in a skin model of chronic wounds. J Dermatol Sci1996; 13:56–62.
